Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple Sclerosis at ECTRIMS

Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple Sclerosis at ECTRIMS

Publication date: Sep 10, 2019

Following Ocrevus treatment, blood neurofilament light chain (NfL) levels were lowered to a healthy donor range [1] in relapsing MS (RMS) and primary progressive MS (PPMS) patients.

In the Phase III OPERA I study in RMS and the ORATORIO study in PPMS, blood NfL levels were significantly lower after treatment with Ocrevus.

Concepts Keywords
35th Congress Interferon
Biomarker PPMS
Blood Neurofilament light polypeptide
Blood Serum Multiple sclerosis
Brain Genentech
Cerebrospinal Fluid Ocrelizumab
Genentech Breakthrough therapy
Interferon Beta 1a Biomarkers
Multiple Sclerosis Medicine
Nerve Clinical medicine
Neurofilament Branches of biology
NfL MS
OPERA
Progressive
Stockholm

Semantics

Type Source Name
gene UNIPROT MAGEE1
gene UNIPROT TNFSF14
gene UNIPROT NEFL
drug DRUGBANK Ocrelizumab
disease MESH Disease Progression
disease MESH Multiple Sclerosis
disease DOID Multiple Sclerosis
drug DRUGBANK Nonoxynol-9
disease MESH primary progressive multiple sclerosis
disease DOID primary progressive multiple sclerosis
drug DRUGBANK Interferon beta-1a
gene UNIPROT CSF2

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *